Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop aims to zap dry eye discomfort in weeks

NCT ID NCT07268599

Symptom relief Sponsor: Colvard Kandavel Eye Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Acoltremon 0.003% eye drops can quickly relieve symptoms like burning, irritation, and blurriness in people with moderate-to-severe dry eye disease. Fifty adults will use the drops as directed and report their symptom changes over 28 days. The goal is to see how fast and effectively the treatment eases discomfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acoltremon 0.003% eye drops
What this could lead to
If successful, this could offer a fast-acting option to ease dry eye symptoms like burning, irritation, and blurriness.
What could go wrong
This is a small, early-phase trial with only 50 participants and no placebo group, so results may not be conclusive or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Colvard-Kandavel Eye Center patients

Ages

18 to 60 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older with clinical diagnosis of DED within past 6 months * Use or desire for artificial tears for DED symptoms within past 2 months * OSDI score \>25 and \<50 at Screening * TBUT \<10 seconds * Baseline tCFS score ≥2 and ≤15 (modified NEI) Exclusion Criteria: * History of corneal or conjunctival surgery * History of herpes zoster ophthalmicus, herpes simplex virus keratitis, or other viral corneal infection * History of neurotrophic keratitis * Prior significant facial trauma or sinus surgery * Mental or physical condition impairing ability to complete questionnaires * Use of Restasis®, Xiidra®, or Miebo within 30 days * Use of other topical anti-inflammatory medications within 30 days * Use of varenicline nasal spray within 30 days * Use of artificial tears within 2 hours prior to screening or during study period * Glaucoma requiring topical therapy * Contact lens or eyelid scrub use within 7 days * Punctal plugs within 14 days * Oxervate historical use * Amniotic membrane or Serum Tears historical use * History of Sjögren's disease * History of LASIK within 1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease (DED) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease (DED)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Colvard-Kandavel Eye Center

    Encino, California, 91316, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.